Miraculins Launches Warrant Exercise Incentive Program | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins has launched an early-exercise warrant incentive program intended to encourage the early exercise of up to 7.8 million of its outstanding unlisted warrants.

The Winnipeg, Manitoba-based firm said that the warrants entitle holders to acquire one share of common stock at a price of C$.10 (US$.10) until June 17, 2011. The warrant holders are now being offered an incentive consisting of a half warrant in addition to the common share issuable for each warrant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.